Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

USP48 stabilizes YBX1 to enforce a Wnt-driven stemness circuit and osimertinib resistance in EGFR-mutant NSCLC.

Cancer letters - 28 Aug 2026

Li Kun-Chao, Gan Shuai, Lu Shan, Yuan Tian-Kai, Dong Ze-Ning, Gao Chao, Chen Shi-Wei, Zhang Ling-Xian, Wang Ding-Guo, Wu Yong-Bing

Abstract excerpt

Osimertinib resistance remains a major obstacle to durable disease control of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), yet the regulatory circuitry that sustains a stem-like drug-tolerant state is incompletely understood. Here, the deubiquitinase (DUB) USP48 was identified as a critical determinant of acquired resistance through stabilization of Y-box binding protein 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Indoles

Share to Neoplastic Stem Cells

Share to Pyrimidines

Share to Wnt Signaling Pathway

Share to Xenograft Model Antitumor Assays

Share to Y-Box-Binding Protein 1

Source

Identifiers

PMID: 42142703
DOI: 10.1016/j.canlet.2026.218587

Genes

USP48
YBX1
EGFR
PTK7
TCF7L2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

USP48 stabilizes YBX1 to enforce a Wnt-driven stemness circuit and osimertinib resistance in EGFR-mutant NSCLC.PMID 42142703Read ↗

Targeting USP13 ‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancerSemantic proximity Read ↗

TRMT1-Mediated tRNA m22G Modification Drives Osimertinib Resistance via the ATXN3/USP25 Axis in Lung AdenocarcinomaSemantic proximity Read ↗

USP7-mediated ERβ stabilization mitigates ROS accumulation and promotes osimertinib resistance by suppressing PRDX3 SUMOylation in non-small cell lung carcinoma.Semantic proximity Read ↗

Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.Semantic proximity Read ↗

CRISPR screens reveal YAP/TEAD axis as a mediator of drug-tolerant cells in EGFR-mutant NSCLC.Semantic proximity Read ↗

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemnessSemantic proximity Read ↗

P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

CRISPR Screens Reveal YAP/TEAD Axis as a Mediator of Drug-Tolerant Cells in EGFR- Mutant NSCLCSemantic proximity Read ↗

Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.Semantic proximity Read ↗

USP29 enhances chemotherapy-induced stemness in non-small cell lung cancer via stabilizing Snail1 in response to oxidative stressSemantic proximity Read ↗

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSemantic proximity Read ↗

Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.